109170 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar 2'-O-R Modification
KRAS nucleic acids and uses thereof
#2102Therapeutic compositions
#2103Downregulating miR-132 for the treatment of lipid related disorders
#2104Methods of Inducing Exon Skipping
#2105MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
#2106METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
#2107TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF
#2108COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2109MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#2110Methods of Inducing Exon Skipping
#2111Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2112Post-selec modification methods
#2113Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
#2114Modified antimir-138 oligonucleotides
#2115NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY
#2116Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#2117Allele-specific therapy for huntington disease haplotypes
#2118Targeting ligands for therapeutic compounds
#2119COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2120Interfering RNA molecules
#2121Antisense oligonucleotides useful in treatment of Pompe disease
#2122PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
#2123NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF BETA-2GPI
#2124NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF BETA-2GPI
#2125Interfering RNA molecules
#2126Interfering RNA molecules
#2127Interfering RNA molecules
#2128SCN8A splice modulating oligonucleotides and methods of use thereof
#2129RAS exon 2 skipping for cancer treatment
#2130MicroRNA compounds and methods for modulating miR-21 activity
#2131GNAQ targeted dsRNA compositions and methods for inhibiting expression
#2132IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
#2133NUCLEIC ACID LIPID PARTICLE FORMULATIONS
#2134Twist signaling inhibitor compositions and methods of using the same
#2135MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#2136Antisense oligonucleotide directed removal of proteolytic cleavage sites, the HCHWA-D mutation, and trinucleotide repeat expansions
#2137METHODS OF TREATING ISCHEMIA-REPERFUSION INJURY WITH siRNAS
#2138COMPOSITIONS AND METHODS FOR TREATING CANCER
#2139TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#2140COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES
#2141MODULATION OF ENHANCER RNA MEDIATED GENE EXPRESSION
#2142Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
#2143Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
#2144MicroRNA compounds and methods for modulating miR-122
#2145Targeting microRNAs for metabolic disorders
#2146Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
#2147Antisense oligonucleotide compositions
#2148dsRNA for treating viral infection
#2149Oligonucleotide comprising an inosine for treating DMD
#2150Oligomers
#2151Modifications for antisense compounds
#2152RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#2153Targeting microRNAs for the treatment of fibrosis
#2154Targeting human satellite II (HSATII)
#2155Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#2156Antisense compounds targeting apolipoprotein E receptor 2
#2157Oligonucleotides for inducing paternal UBE3A expression
#2158Compositions and methods for the treatment of influenza infection
#2159Exosomal loading using hydrophobically modified oligonucleotides
#2160Delivery of agents using interfering nanoparticles
#2161Antisense compounds
#2162Exon skipping technology in VCP disease
#2163Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
#2164Compositions and methods for decreasing tau expression
#2165Compositions for modulating Ataxin 2 expression
#2166Methods for modulating Ataxin 2 expression
#2167MIR-21-3P INHIBITORS IN SKIN DISORDERS
#2168Compositions and methods for modulating growth hormone receptor expression
#2169siRNA structures for high activity and reduced off target
#2170APTAMERS FOR TOPICAL DELIVERY
#2171Compositions and methods for modulating complement factor B expression
#2172Methods and compositions for treating a Serpinc1-associated disorder
#2173Antisense oligonucleotides for the treatment of Usher syndrome type 2
#2174Small interfering RNA and pharmaceutical composition and method for inhibiting galectin-12 expression and/or enhancing lipolysis containing the same
#2175Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein
#2176Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#21775' TARGETING OLIGONUCLEOTIDES FOR MODULATING RNA
#2178COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#2179Combination of Anti-Clusterin Oligonucleotide with HSP90 Inhibitor for the Treatment of Prostate Cancer
#2180IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE
#2181Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
#2182Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
#2183LIPID FORMULATION
#2184Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3
#2185Compositions and methods for inhibiting expression of RRM2 genes
#2186Inhibition of PCSK9 through RNAI
#2187MOLECULES AND AGENTS FOR TREATING HEPATITIS B VIRUS
#2188Double-stranded oligonucleotides
#2189Organic compositions to treat APOC3-related diseases
#2190Targeting microRNAS for the treatment of liver cancer
#2191Nucleic acid drug for inducing skipping of variant exon of CD44 gene and increasing expression of normal type CD44 mRNA
#2192Amine cationic lipids and uses thereof
#2193Aptamers against EGFR and therapeutic uses thereof
#2194LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF
#2195Small molecules that enhance the activity of oligonucleotides
#2196Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#2197Methods and compositions for modulating apolipoprotein (a) expression
#2198Serpina1 iRNA compositions and methods of use thereof
#2199METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#2200Modulation of gene expression and screening for deregulated protein expression
#2201Compositions and methods for inhibiting gene expression of LPA
#2202siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
#2203COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#2204METHODS AND COMPOSITIONS FOR INCREASING EFFICIENCY OF TARGETED GENE MODIFICATION USING OLIGONUCLEOTIDE-MEDIATED GENE REPAIR
#2205METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS
#2206Targeting hepatitis B virus (HBV) host factors
#2207MODULATORS OF GROWTH HORMONE RECEPTOR
#2208RNAi-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma
#2209Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
#2210Organic compositions to treat HSF1-related diseases
#2211Antisense nucleic acids
#2212Targeting microRNAs for metabolic disorders
#2213METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
#2214Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
#2215VASCULAR RE-MODELLING
#2216Polycomb-associated non-coding RNAs
#2217CRISPR-BASED COMPOSITIONS AND METHODS OF USE
#2218CRISPR-based compositions and methods of use
#2219CRISPR-based compositions and methods of use
#2220METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#2221Methods for the treatment of Leber congenital amaurosis
#22222′/3′/5′-(R/S)-serinyl functionalized oligonucleotides
#2223Linkage modified oligomeric compounds
#2224LIPID NANO PARTICLES COMPRISING CATIONIC LIPID FOR DRUG DELIVERY SYSTEM
#2225Compositions for modulating SOD-1 expression
#2226MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#2227METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
#2228OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
#2229Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2230SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE
#2231MODULATION OF FACTOR 11 EXPRESSION
#2232COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE I (DMI)
#2233RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
#2234RNAi agents modified at the 4′-C position
#2235Agents useful in treating facioscapulohumeral muscular dystrophy
#2236RNA complexes that inhibit melanin production
#2237Small molecule conjugates for intracellular delivery of biologically active compounds
#2238Polycomb-associated non-coding RNAs
#2239Oligomers
#2240Method of Treating Cancer by Inhibition of DNA Repair Proteins
#2241COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN CANCER
#2242Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
#2243RNA interference in skin indications
#2244Compositions and methods for inhibition of nucleic acids function
#2245SiRNA targeting PRK2, which is hepatitis C virus therapeutic agent
#2246Modulation of prekallikrein (PKK) expression
#2247LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE
#2248RNAi inhibition of alpha-ENaC expression
#2249Polycomb-associated non-coding RNAS
#2250Method of treating influenza A
#2251Molecular re-engineering of excitation-inhibition balance in memory circuits
#2252Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
#2253Modulation of transthyretin expression
#2254Compositions and their uses directed to huntingtin
#2255Methods and compositions for neuroprotection
#2256Methods and compositions for modulating alpha-1 antitrypsin expression
#2257Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#2258RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
#2259Polycomb-associated non-coding RNAs
#2260Modulation of Exon Recognition in Pre-mRNA By Interfering with the Secondary RNA Structure
#2261Polycomb-associated non-coding RNAs
#2262Double stranded oligonucleotide compounds comprising positional modifications
#2263Compositions and Methods for Inhibition of PCSK9 Genes
#2264Compositions and methods for inhibiting expression of the PCSK9 gene
#2265METHODS AND COMPOSITIONS FOR REDUCING VIRAL GENOME AMOUNTS IN A TARGET CELL
#2266NUCLEIC ACID CHEMICAL MODIFICATIONS
#2267POST-SYNTHETIC CHEMICAL MODIFICATION OF RNA AT THE 2'-POSITION OF THE RIBOSE RING VIA "CLICK" CHEMISTRY
#2268MODULATION OF TRANSTHYRETIN EXPRESSION
#2269Ketohexokinase (KHK) iRNA compositions and methods of use thereof
#2270Oligonucleotide modulators of the toll-like receptor pathway
#22715′ triphosphate oligonucleotide with blunt end and uses thereof
#22725′ triphosphate oligonucleotide with blunt end and uses thereof
#2273NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF BETA-2GPI
#2274Materials and methods for modulation of tendon healing
#2275Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
#2276RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular Angiogenesis
#2277Methods for treatment of alport syndrome
#2278Sequence-specific inhibition of small RNA function
#2279FULLY STABILIZED ASYMMETRIC SIRNA
#2280Modulation of huntingtin expression
#2281Dual Targeting siRNA Agents
#2282SiRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
#2283Double-stranded RNA compounds to CASP2 and uses thereof
#2284METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES
#2285Immunotherapy of cancer
#2286Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
#2287Compositions of asymmetric interfering RNA and uses thereof
#2288SiRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene
#2289MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS
#2290MEANS FOR LUNG SPECIFIC DELIVERY
#2291Complement component iRNA compositions and methods of use thereof
#2292Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions
#2293Haplotype Based Generalizable Allele Specific Silencing for Therapy of Cardiovascular Disease
#2294Methods for Treating or Preventing Ophthalmological Conditions
#2295Small interference RNAs, uses thereof and method for inhibiting the expression of PLK1 gene
#2296Guide RNA with chemical modifications
#2297METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
#2298Modulation of T cell signaling threshold and T cell sensitivity to antigens
#2299Organic compositions to treat beta-ENaC-related diseases
#2300Disulfide-containing alkyne linking agents
#2301Targeting microRNA-26a/b for the treatment of neurodegenerative disease
#2302NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND USES THEREOF
#2303Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
#2304COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION
#2305MODIFIED iRNA AGENTS
#2306OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD
#2307Compositions and methods for inhibiting expression of the LECT2 gene
#2308RNA targeting in alpha-synucleinopathies
#2309RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#2310Compositions and Methods for Inhibiting Expression of Transthyretin
#2311RNA INTERFERENCE MEDIATED INHIBITION OF ISOCITRATE DEHYDROGENASE (IDH1) GENE EXPRESSION
#2312POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS
#2313SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2314Non-liposomal systems for nucleic acid delivery
#2315MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#2316MicroRNA compounds and methods for modulating miR-122
#2317Compositions for modulating C9ORF72 expression
#2318Method for reducing circulating leukocytes in a human subject
#2319Antisense compounds targeting genes associated with cystic fibrosis
#2320Compositions and methods for inhibiting expression of the ALAS1 gene
#2321Reduced size self-delivering RNAI compounds
#2322Complement component C5 iRNA compositions and methods of use thereof
#2323Reducing intron retention
#2324Compositions and methods for modulating neuronal excitability and motor behavior
#2325Formats for organic compounds for use in RNA interference
#2326Serpina1 siRNAs: compositions of matter and methods of treatment
#2327siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene
#2328Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
#2329Toll-like receptor 9 antagonist and methods of use thereof
#2330Modulation of apolipoprotein C-III expression
#2331METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#2332Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
#2333COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#2334siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof
#2335MODULATORS OF COMPLEMENT FACTOR B
#2336Notch 1 specific siRNA molecule
#2337Nucleic acids and methods for the treatment of Pompe disease
#2338Compositions and methods for treating lung disease and injury
#2339Genetic inhibition by double-stranded RNA
#2340Antisense-induced exon2 inclusion in acid alpha-glucosidase
#2341Targeting microRNAs for metabolic disorders
#2342COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF FRATAXIN
#2343Methods and compositions for selecting siRNA of improved functionality
#2344Compositions and methods for inhibiting expression of mutant EGFR gene
#2345Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
#2346Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals
#2347MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#2348Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene
#2349Compositions and methods for modulating angiopoietin-like 3 expression
#2350Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
#2351Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#2352Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
#2353Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA
#2354Compositions and methods for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
#2355Compositions and methods for increasing erythropoietin (EPO) production
#2356PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
#2357Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#2358CRISPR-based compositions and methods of use
#2359Methods and compositions for the specific inhibition of HIF-1α by double-stranded RNA
#2360MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#2361MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE
#2362Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ)
#2363UNA single stranded oligomers for therapeutics
#2364RIG-I ligands and methods for producing them
#2365Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
#2366TMPRSS6 iRNA compositions and methods of use thereof
#2367Compositions and methods for inhibiting expression of TMPRSS6 gene
#2368Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure
#2369Oligomers with improved off-target profile
#2370Double-stranded agents for delivering therapeutic oligonucleotides
#2371Micro-RNA family that modulates fibrosis and uses thereof
#2372Micro-RNA family that modulates fibrosis and uses thereof
#2373Micro-RNA family that modulates fibrosis and uses thereof
#2374Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
#2375MicroRNA and methods for inhibiting same
#2376ANTISENSE COMPOUNDS AND USES THEREOF
#2377Interfering RNA molecules
#2378Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
#2379TARGETING DOMAIN AND RELATED SIGNAL ACTIVATED MOLECULAR DELIVERY
#2380Reduced size self-delivering RNAi compounds
#2381COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS
#2382COMPOSITIONS AND METHODS FOR MODULATING FOXP3 EXPRESSION
#2383Dosages and methods for delivering lipid formulated nucleic acid molecules
#2384Method of nonspecific target capture of nucleic acids
#2385Inhibition of MAP4K4 through RNAi
#2386SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA
#2387RNA interference in ocular indications
#2388Compositions and methods for inhibiting expression of the ALAS1 gene
#2389Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases
#2390METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING
#2391Complement component C5 iRNA compositions and methods of use thereof
#2392Modulation of HSP47 expression
#2393Targeting microRNAs for the treatment of fibrosis
#2394DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF
#2395Compositions and methods for inhibiting expression of the HAMP gene
#2396Compositions and methods for modulating apolipoprotein (a) expression
#2397Compositions and methods for modulating apolipoprotein C-III expression
#2398Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
#2399Therapeutic compositions
#2400Compositions and methods for silencing marburg virus gene expression